<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945256</url>
  </required_header>
  <id_info>
    <org_study_id>03-213</org_study_id>
    <secondary_id>R01AG021539</secondary_id>
    <nct_id>NCT00945256</nct_id>
  </id_info>
  <brief_title>Muscle Perfusion and Protein Metabolism in Elderly</brief_title>
  <official_title>A Phase I Trial Examining Muscle Perfusion and Protein Metabolism in Elderly and Young</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to examine the role skeletal muscle perfusion plays in
      mediating muscle protein synthesis in healthy older and younger individuals. The
      investigators hypothesized that normalization of muscle perfusion in older men and women via
      exercise or infusion of a vasodilator would enhance nutritive flow and skeletal muscle
      protein synthesis in the elderly similar to that of their younger counterparts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to examine muscle protein metabolism in healthy young and
      elderly subjects during pharmacologic vasodilation of the lower limb vasculature in
      combination with increased amino acids delivery. We obtained femoral arteriovenous blood
      samples and v. lateralis muscle biopsies during a primed continuous infusion of L-[ring-13C6]
      Phenylalanine. Muscle protein kinetics were measured in the basal state and during a 180 min
      infusion of sodium nitroprusside (SNP) and amino acids (Premsol 10%) (SNP+AA). Skeletal
      muscle microvascular recruitment and flow were measured during the basal state and SNP+AA
      using contrast-enhanced ultrasound (CEU).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mixed Muscle Fractional Synthesis Rate (FSR)</measure>
    <time_frame>Acute ( 8 hours)</time_frame>
    <description>The rate at which the body makes new muscle was assessed by determining the fractional synthesis rate (FSR). This technique determines how quickly new amino acids are used to make muscle. In this technique, a special (but natural and non-radioactive) version of an amino acid is infused into the blood. This special version of the amino acid is heavier than the most common version the same amino acid. This property allows it to be identified in a muscle sample. By determining how much of the special amino acid has accumulated over time in a muscle sample, the fractional synthesis rate can be determined. For example, if the rate were such that 1 of every 100 amino acids were of the special type after 1 day, the fractional synthesis rate would be 1% per day. In other words, 1/100 of the muscle would be newly made each day.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Young Aerobic Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 minutes of treadmill walking at 40% VO2 peak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Aerobic Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 minutes of treadmill walking at 40% VO2 peak</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Young Sodium Nitroprusside</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Sodium Nitoprusside</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Sodium Nitroprusside and Amino Acid Drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic Exercise</intervention_name>
    <description>45 minuties of treadmill walking was completed at 40% VO2 peak</description>
    <arm_group_label>Young Aerobic Exercise</arm_group_label>
    <arm_group_label>Elderly Aerobic Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitroprusside</intervention_name>
    <description>Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min</description>
    <arm_group_label>Young Sodium Nitroprusside</arm_group_label>
    <arm_group_label>Elderly Sodium Nitoprusside</arm_group_label>
    <arm_group_label>Elderly Sodium Nitroprusside and Amino Acid Drink</arm_group_label>
    <other_name>Nitropress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Amino Acid Drink</intervention_name>
    <description>7.5 gram Amino Acid drink</description>
    <arm_group_label>Elderly Sodium Nitroprusside and Amino Acid Drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All inclusion criteria must be fulfilled throughout the study. At enrollment, subjects must
        fit the following criteria:

          1. Age: young 18-40 yrs; elderly 60-85 yrs.

          2. Availability of transportation (i.e., subjects must be able to provide their own
             transportation to UTMB).

          3. Ability to sign informed consent (score &gt;24 on 30 item mini-mental status exam and no
             errors on assessment of judgment).

        Exclusion Criteria:

        None of the following exclusion criteria should be present at enrollment or throughout the
        study:

          1. Patients with limiting or unstable angina or who demonstrate cardiac abnormalities
             such as &gt; 0.2 mV horizontal or downsloping ST segment depression, frequent arrhythmias
             (&gt;10 PVC/min), or valvular disease.

          2. Any patient with atrial fibrillation, history of syncope, angina, or congestive heart
             failure.

          3. Patients with vascular disease, as determined by the presence of risk factors of
             peripheral atherosclerosis (i.e., hypertension, obesity, uncontrolled diabetes, and
             evidence of venous or arterial insufficiency upon palpation of femoral, popliteal, and
             pedal arteries).

          4. Peripheral vascular disease as determined by history or abnormal ankle-brachial index
             by Doppler (&lt; 1.0).

          5. Any subject with blood pressure on three consecutive measurements taken at rest on
             separate occasions that has a systolic pressure &gt;170 mm Hg or a diastolic blood
             pressure &gt;100 mm Hg will be excluded. Subjects will not be included if they are taking
             blood pressure medication and have a blood pressure above these criteria.

          6. Any person HIV-seropositive, with active hepatitis, or any other immunosuppressive or
             autoimmune disease.

          7. Any patient taking beta blockers, vasodilators, angiotensin-converting enzyme
             inhibitors, calcium channel blockers, or alpha blockers.

          8. Any patient with uncontrolled metabolic diseases including any patient with liver or
             renal disease.

          9. Glucose intolerance: fasting plasma glucose concentration 110-126 mg/dL (6.1-7 mmol/L)
             and/or 2-h plasma glucose 140-200 mg/dL (7.8-11.1 mmol/L) during oral glucose
             tolerance test (OGTT).

         10. Currently in muscle strengthening program.

         11. Total knee replacement or moderate to severe degenerative joint disease of knees.

         12. Anemia (hemoglobin &lt;13 g/dL in males or &lt;12 g/dL in females).

         13. Any history of hypo- or hyper-coagulation disorders, including patients taking
             Coumadin or with a history of deep venous thrombosis (DVT) or pulmonary embolism (PE)
             at any point in their lifetimes.

         14. Currently taking aspirin and cannot stop for 7 days (i.e., medical indication for
             continued aspirin such as transient ischemic attacks).

         15. Presence of acute illness or metabolically unstable chronic illness.

         16. Heart disease requiring therapy or recent myocardial infarction (less than 1 year)

         17. Currently on weight-loss diet.

         18. Active cancer or in short-term remission (less than 3 years).

         19. Alcohol or drug abuse.

         20. History of &gt;20 packs per year cigarette smoking.

         21. Recent (within 6 months) ingestion or injection or transdermal administration of
             anabolic steroids, corticosteroids, estrogens, or progestagens.

         22. History of falls (1 fall in the past year which required medical attention, or more
             than 2 falls/year regardless of severity).

         23. Allergy to iodides, penicillin or shellfish.

         24. Any subject with a know hypersensitivity to octafluoropropane.

         25. Any subject with a cardiac shunt.

         26. Any subject with chronic obstructive pulmonary disease (COPD).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melinda Sheffield-Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTMB</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <results_first_submitted>March 28, 2013</results_first_submitted>
  <results_first_submitted_qc>November 30, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2016</results_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolism</keyword>
  <keyword>exercise</keyword>
  <keyword>sodium nitroprusside</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Young groups: Ages 18 - 40; Elderly groups: Ages 60 - 85</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Young Aerobic Exercise</title>
          <description>45 minutes of treadmill walking completed at 40% VO2 peak</description>
        </group>
        <group group_id="P2">
          <title>Elderly Aerobic Exercise</title>
          <description>45 minutes of treadmill walking at 40% VO2 peak.</description>
        </group>
        <group group_id="P3">
          <title>Young Sodium Nitroprusside</title>
          <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
        </group>
        <group group_id="P4">
          <title>Elderly Sodium Nitroprusside</title>
          <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
        </group>
        <group group_id="P5">
          <title>Elderly Sodium Nitroprusside and Amino Acid Drink</title>
          <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5 gram amino acid drink taken orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Young Aerobic Exercise</title>
          <description>45 minutes of treadmill walking completed at 40% VO2 peak.</description>
        </group>
        <group group_id="B2">
          <title>Elderly Aerobic Exercise</title>
          <description>45 minutes of treadmill walking completed at 40% VO2 peak.</description>
        </group>
        <group group_id="B3">
          <title>Young Sodium Nitroprusside</title>
          <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
        </group>
        <group group_id="B4">
          <title>Elderly Sodium Nitroprusside</title>
          <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
        </group>
        <group group_id="B5">
          <title>Elderly Sodium Nitroprusside and Amino Acid Drink</title>
          <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5 gram amino acid drink taken orally.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="16"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="5.9"/>
                    <measurement group_id="B2" value="67.4" spread="5.1"/>
                    <measurement group_id="B3" value="26.4" spread="5.0"/>
                    <measurement group_id="B4" value="68.1" spread="5.9"/>
                    <measurement group_id="B5" value="67.1" spread="4.4"/>
                    <measurement group_id="B6" value="49.2" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mixed Muscle Fractional Synthesis Rate (FSR)</title>
        <description>The rate at which the body makes new muscle was assessed by determining the fractional synthesis rate (FSR). This technique determines how quickly new amino acids are used to make muscle. In this technique, a special (but natural and non-radioactive) version of an amino acid is infused into the blood. This special version of the amino acid is heavier than the most common version the same amino acid. This property allows it to be identified in a muscle sample. By determining how much of the special amino acid has accumulated over time in a muscle sample, the fractional synthesis rate can be determined. For example, if the rate were such that 1 of every 100 amino acids were of the special type after 1 day, the fractional synthesis rate would be 1% per day. In other words, 1/100 of the muscle would be newly made each day.</description>
        <time_frame>Acute ( 8 hours)</time_frame>
        <population>FSR was not calculated for the Elderly Sodium Nitroprusside with Amino Acid Drink arm of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Young Aerobic Exercise</title>
            <description>45 minutes of treadmill walking completed at 40% VO2 peak.</description>
          </group>
          <group group_id="O2">
            <title>Elderly Aerobic Exercise</title>
            <description>45 minutes of treadmill walking completed at 40% VO2 peak.</description>
          </group>
          <group group_id="O3">
            <title>Young Sodium Nitroprusside</title>
            <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
          </group>
          <group group_id="O4">
            <title>Elderly Sodium Nitroprusside (SNP)</title>
            <description>Sodium Nitroprusside (Nitropress) given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
          </group>
          <group group_id="O5">
            <title>Elderly Sodium Nitroprusside and Amino Acid Drink</title>
            <description>Sodium Nitroprusside (Nitropress) given as a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and a 7.5g amino acid drink taken orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Mixed Muscle Fractional Synthesis Rate (FSR)</title>
          <description>The rate at which the body makes new muscle was assessed by determining the fractional synthesis rate (FSR). This technique determines how quickly new amino acids are used to make muscle. In this technique, a special (but natural and non-radioactive) version of an amino acid is infused into the blood. This special version of the amino acid is heavier than the most common version the same amino acid. This property allows it to be identified in a muscle sample. By determining how much of the special amino acid has accumulated over time in a muscle sample, the fractional synthesis rate can be determined. For example, if the rate were such that 1 of every 100 amino acids were of the special type after 1 day, the fractional synthesis rate would be 1% per day. In other words, 1/100 of the muscle would be newly made each day.</description>
          <population>FSR was not calculated for the Elderly Sodium Nitroprusside with Amino Acid Drink arm of the study.</population>
          <units>Fractional Synthesis Rate (pecent/hour)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-intervention (either exercise or SNP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.005"/>
                    <measurement group_id="O2" value="0.070" spread="0.006"/>
                    <measurement group_id="O3" value="0.066" spread="0.01"/>
                    <measurement group_id="O4" value="0.070" spread="0.004"/>
                    <measurement group_id="O5" value="NA">FSR was not calculated for this arm of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post -intervention (either exercise or SNP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.098" spread="0.009"/>
                    <measurement group_id="O2" value="0.111" spread="0.011"/>
                    <measurement group_id="O3" value="0.090" spread="0.008"/>
                    <measurement group_id="O4" value="0.095" spread="0.009"/>
                    <measurement group_id="O5" value="NA">FSR was not calculated for this arm of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time frame for Adverse Event Reporting is the study date and one week past the study date to assess any problems with muscle biopsies, catheter placement.</time_frame>
      <desc>Adverse events were self reported by subjects to clinical research staff.</desc>
      <group_list>
        <group group_id="E1">
          <title>Young Aerobic Exercise</title>
          <description>45 minutes of treadmill walking completed at 40% VO2 peak.</description>
        </group>
        <group group_id="E2">
          <title>Elderly Aerobic Exercise</title>
          <description>45 minutes of treadmill walking completed at 40% VO2 peak.</description>
        </group>
        <group group_id="E3">
          <title>Young Sodium Nitroprusside</title>
          <description>Sodium Nitroprusside (Nitropress) given as a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
        </group>
        <group group_id="E4">
          <title>Elderly Sodium Nitroprusside</title>
          <description>Sodium Nitroprusside (Nitropress) given as a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min.</description>
        </group>
        <group group_id="E5">
          <title>Elderly Sodium Nitroprusside and Amino Acid Drink</title>
          <description>Sodium Nitroprusside (Nitropress) given as a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5 grams of amino acids taken orally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>The subject developed cellulitis near the placement of the femoral catheters 3 days post procedure.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Back pain in direct relation to infusion of Definity Microbubbles</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness at biopsy site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Swelling at femoral catheter site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Melinda Sheffield-Moore, Professor of Medicine</name_or_title>
      <organization>University of Texas Medical Branch</organization>
      <phone>409-772-8707</phone>
      <email>melmoore@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

